Page 30 - Solid Biosciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator Ladies and gentlemen, thank you for standing by, and welcome to the Solid Biosciences update call. [Operator instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Mr. Tim Palmer, corporate communications manager at Solid Biosciences. Sir, you may begin. Corporate Communications Manager Good morning. Thank you, operator. Before we get started, I would like to remind everyone that during this conference call, we may make forward-looking statements, including statements about the company's financial...

• Sogou (NYSE:SOGO) is projected to report earnings for its first quarter. • Sohu.com (NASDAQ:SOHU) is estimated to report earnings for its first quarter. • Diversey Holdings (NASDAQ:DSEY) is likely to report quarterly earnings at $0.04 per share on revenue of $616.76 million. • Solid Biosciences (NASDAQ:SLDB) is projected to report earnings for its second quarter. • Vasta Platform (NASDAQ:VSTA) is expected to report earnings for its first quarter. • Fangdd Network Group (NASDAQ:DUO) is likely to report quarterly loss at $0.10 per share on revenue of $41.72 million. • argenx (NA...

Roche Holdings AG Basel ADR (OTC: RHHBY) said Monday that it has signed a licensing agreement with Sarepta Therapeutics Inc (NASDAQ: SRPT) to acquire the commercial rights to the latter's investigational gene therapy asset SRP-9001 outside of the U.S. The asset is being evaluated in... Read More...

Adverum Files Investor Presentation Highlighting Significant Strategic Progress and Purpose-Built Board to Oversee Stockholder Value Creation Urges Stockholders to Vote the WHITE Proxy Card “FOR” ALL of Adverum’s Three Highly Qualified, Diverse and Independent Directors: Dawn Svoronos, Reed V. Tuckson, M.D. and Thomas Woiwode, Ph.D. REDWOOD CITY, Calif., April 22, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that it has filed a new investor present...

These drugmaker stocks may have been hammered down to bargain-bin prices.